RNA, U1 small nuclear 146, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-146P profile across patient tissues and cancer cell-line models. RNU1-146P expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RNU1-146P is differentially expressed in 2, with the highest sampling consensus in ESCA. Additionally, RNU1-146P RNA expression shows 6,122 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight OV, ESCA, and STAD as cancer lineages where RNU1-146P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-146P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-146P survival associations across molecular data types. RNU1-146P RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-146P RNA expression–survival associations across cancer types. High RNU1-146P expression shows unfavorable associations in OV, LIHC, STAD, CESC, BRCA and ACC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify OV as the clearest survival context for RNU1-146P RNA expression.
This table summarizes RNU1-146P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-146P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-146P shows lower tumor expression in ESCA and higher tumor expression in LUSC. The ESCA box plot shows higher RNU1-146P RNA expression in normal versus tumor tissue (log2 FC = −0.370, t-test p < 0.001).
This table shows molecular features associated with RNU1-146P in patient tissues and cancer cell lines. In patient samples, RNU1-146P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
